-92%

est. 2Y upside i

HealthcareSeed

Instant lab tests on your smartphone

Rank

#1546

Sector

Healthtech

Est. Liquidity

~6Y

Data Quality

Data: High

This opportunity offers significant potential upside driven by a large market and strong growth, but is tempered by substantial regulatory hurdles and the presence of well-funded incumbents in a market with a thin competitive moat.

Last updated: February 16, 2026

Bull (20%)+400%

Neodocs successfully navigates regulatory landscapes, expands its test offerings and geographic reach, and achieves significant market adoption, leading to a lucrative acquisition.

Base (40%)+50%

Neodocs continues its strong growth in India and achieves limited international success, but faces ongoing competitive and regulatory challenges, resulting in a modest return.

Bear (40%)-90%

Neodocs struggles with regulatory approvals, fails to differentiate effectively against well-funded competitors, or faces capital constraints, leading to a significant loss of investment.

Est. time to liquidity~6.0 years

Community

Valuation Sentiment

Our model estimates -92% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.